Evofem Biosciences, Inc.

Based in the US, Evofem Biosciences, Inc. is a biotechnology company focused on innovative women's reproductive healthcare solutions, particularly through its hormone-free contraceptive product, Phexxi®. Evofem Biosciences, Inc. specializes in women's reproductive healthcare, particularly in developing non-hormonal birth control methods.

Founded in 2015 in San Diego, California, the company has undergone significant changes in its strategic direction. Most recently, in December 2023, the company was acquired by Aditxt, Inc. for USD 100 mn. Evofem has closed a total of 5 deals, with its latest deal focusing on enhancing its growth initiatives.

CEO Joseph Pike leads the company alongside Saundra Pelletier. Evofem Biosciences, Inc. specializes in providing innovative women’s reproductive healthcare solutions, with its flagship product being Phexxi®—a hormone-free, on-demand prescription vaginal gel. Launched in 2020, Phexxi is designed to prevent pregnancy by creating an acidic environment that inhibits sperm motility, allowing women to use it discretionarily within a 0-60 minute window prior to intercourse.

The company targets women in the United States seeking alternatives to hormonal contraceptives, particularly those who cannot use hormones due to medical conditions. Evofem aims to expand its market reach internationally, exploring commercialization opportunities aligned with the growing trend towards natural healthcare products. Evofem Biosciences generates revenue primarily through the sales of its Phexxi product, which is available via prescription in pharmacies and through healthcare providers. The company collaborates with payers and pharmacy benefit managers (PBMs) to ensure that Phexxi is accessible at no cost to patients under the Affordable Care Act (ACA).

In its most recent fiscal year, 2024, the company reported revenue of USD 19. 36 mn and an EBITDA of USD -7. 03 mn. Evofem's revenue trajectory has shown growth, with increasing acceptance of Phexxi among its target demographic, indicating a positive trend in net sales over multiple consecutive quarters.

With the recent acquisition by Aditxt, Inc. in December 2023, Evofem Biosciences, Inc. aims to further enhance its growth. The funding from this acquisition will support the development of new products and market expansion efforts.

The company is currently exploring opportunities for international market entry and potential new product launches aimed at increasing its footprint in women's reproductive health. Specific timelines for new product releases and geographic targets for expansion have not been disclosed.